Search


	Podcast:		OncLive® On Air
	Episode:		22: FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers
	Category:		Science & Medicine
	Duration:		00:12:06
	Publish Date:		2020-07-20 15:08:57
	Description:		In our exclusive interview, Dr. Drilon provided background on use of targeted therapy in advanced NSCLC, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.
	Total Play:		0